Q-omics provides the consensus-scored TAGAP profile across patient tissues and cancer cell-line models. TAGAP expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TAGAP is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TAGAP RNA expression shows 20,968 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where TAGAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAGAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAGAP survival associations across molecular data types. TAGAP RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAGAP RNA expression–survival associations across cancer types. High TAGAP expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, LUAD, KIRC and UCS. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TAGAP RNA expression.
This table summarizes TAGAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TAGAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAGAP shows lower tumor expression in COAD, LUSC, UCEC and LUAD and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher TAGAP RNA expression in tumor versus normal tissue (log2 FC = +1.865, t-test p < 0.001).
This table shows molecular features associated with TAGAP in patient tissues and cancer cell lines. In patient samples, TAGAP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAGAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
